23 / 23
allied
academies
Journal of Pharmacology and Therapeutic Research
Volume 1 Issue 1
Clinical Pharmacy 2017
Notes:
Page 40
December 07-09, 2017 | Rome, Italy
7
th
World Congress on
Clinical Pharmacy and Pharmacy Practice
Doxorubicin versus Idarubicin with overall
survival in adult acute myeloid leukemia
patients
Sherein Mahmoud Ramadan Abdalla, Sherif HA, Rashed R, Rabea
A
and
Elshesheni HA
Cairo University, Egypt
Objective:
The main aim of this retrospective case
control study is to compare the response to doxorubicin
or idarubicin in adult AML patients during the induction
treatment related to patients of the Egyptian National
Cancer Institute (NCI).
Patients and methods:
143 patients from 18 to 60 years
of age with de novo AML were studied. We study the
patients who were admitted in the NCI from January 2013
to January 2016. Standard induction therapy with 3+7.
Cytarabine had to be given in a dose of 100 mg /m2/day
continuous for 7 days; anthracyclines are given for 3 days
being either doxorubicin (DXR) 45 mg /m2 or idarubicin
(IDR) 12 mg /m2. Patients were not eligible if they had
Promyelocytic leukemia.
Results:
Of the 143 patients, 97(67.8%) achieved CR.
Of the 67 patients in the IDR group, 46 (68.7%) achieved
CR, and of 76 in the DXR group, 51 (67.1%) obtained
CR (P=0.8386). In the IDR group, 41 patients (61.2%)
achieved CR after the first course, and in the DXR group,
46 (60.5%) did so (P =0.9320). Early death occurred in
15 (22.3%) in the IDA arm and 24 (31.5%) in the DOXO
arm which was not statistically significant (P=0.2189). 91
patients reached CR, 31 patients experienced relapse, 15
patients in the IDA arm and 16 patients in the DOXO arm.
The median OS was 8 months in IDA arm vs. 6 months
in DOXO (P=0.292). Of 67 patients in the IDR group,
41(61.2%) achieved CR by one induction cycle which cost
4296 EGP/patient (for IDR only) while in the DXR arm,
46(60.5%) obtained CR by one induction cycle which cost
946 EGP/patient (for DXR only).
Conclusion:
Patients who received IDR/Ara-C had no
significant difference compared with those who received
DXR/Ara-C as regards to CR rate, adverse events, and
incidence of relapse. DXR/Ara-C was effective in adult
patients less than age of 60 with newly diagnosed AML.
The low cost of DXR compared to IDR added value in the
treatment’s total cost is important specially for developing
countries like Egypt.
sherein14@hotmail.comSherein Mahmoud Ramadan Abdalla et al., J Pharmacol Ther Res 2017